Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
What is the Expected Growth Rate of the End Stage Renal Disease ESRD Drug Market for the Period 2024 to 2033?
The market size of the end stage renal disease (esrd) drug market has seen a swift expansion lately. Predictions suggest it will surge from a valuation of $116.32 billion in 2023 to reach a size of $132.86 billion in 2024, with a compound annual growth rate (CAGR) of 14.2%. The historical growth observed is likely due to rising cases of end stage renal disease, a burgeoning elderly population, enhanced accessibility to medical services, governmental measures and regulations, and a growing preference for renal replacement treatments.
The market for end stage renal disease (esrd) drugs is anticipated to experience swift expansion in the upcoming years. It is forecasted to escalate to a worth of $232.13 billion in 2028 with a compound annual growth rate (CAGR) of 15.0%. Factors contributing to the growth during the projected period include the introduction of new therapies and drug breakthroughs, an increase in healthcare spending, the escalating global prevalence of chronic kidney diseases, the adoption of personalized medicine strategies, as well as supportive regulations and expedited approvals. Key trends expected during this period are a rising number of end stage renal disease cases, advancements in treatment methods, a heightened focus on precision medicine, the advent of combined therapy techniques, and the integration of technology in healthcare.
Claim Your Free Sample of the Global End Stage Renal Disease ESRD Drug Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
What Factors Are Responsible for the Growth of the end stage renal disease esrd drug Market?
The growing incidence of obesity and diabetes is projected to fuel the expansion of the end-stage renal disease (ESRD) drug market. Obesity, defined as an unusually or excessively fat accumulation that poses a health risk, alongside diabetes, a long-term condition that occurs when the pancreas fails to produce adequate insulin or the body can’t effectively use the insulin created, are both serious concerns. In individuals suffering from renal disease, the management of fluid and electrolyte levels, blood pressure, and waste material removal via dialysis could lead to overall health and wellness improvement. This could contribute to weight loss and the better control of blood sugar levels. As per World Obesity, a US-based organization addressing the research and treatment of obesity, the obese population is anticipated to increase to 892 million by 2025 and then leap to 1,025 million by 2030, as of March 2022. Additionally, as of September 2021, the International Diabetes Federation (IDF), a Belgian umbrella organization, integrated more than 230 national diabetes organizations and estimated about 537 million people between 20 and 79 years old lived with diabetes in 2021. The IDF projects this number to ascend to 643 million by 2030 and 783 million by 2045. Consequently, increasing obesity and diabetes incidences will likely catalyze the ESRD drug market.
Which Segments Are Important for Insight into the End Stage Renal Disease ESRD Drug Market?
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
What Are the Significant Trends Reshaping the End Stage Renal Disease ESRD Drug Sector?
The surge in product innovation is a leading trend in the end-stage renal disease (ESRD) drug market, with key companies vying for dominance via inventive solutions. For example, in April 2022, UK-based biotechnology and pharmaceutical heavyweight, GlaxoSmithKline Plc, had its New Drug Application (NDA) for daprodustat accepted by the US Food and Drug Administration (FDA). This oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) aims to potentially treat patients suffering from chronic kidney disease anaemia (CKD), utilizing pioneering, nobel prize-winning research about cell response and adaptation to oxygen levels.
Order Now for Fast Delivery of Your End Stage Renal Disease ESRD Drug Market Report!
Which Regions Are Essential for the Growth of the End Stage Renal Disease ESRD Drug Market?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2023. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The End Stage Renal Disease ESRD Drug Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the end stage renal disease esrd drug market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The End Stage Renal Disease ESRD Drug Market Include
1. End Stage Renal Disease ESRD Drug Market Executive Summary
2. End Stage Renal Disease ESRD Drug Market Segments
3. End Stage Renal Disease ESRD Drug Market Size And Template Market Growth Rate
4. Key End Stage Renal Disease ESRD Drug Market Trends
5. Major End Stage Renal Disease ESRD Drug Market Drivers
……
25. Key Mergers And Acquisitions In The End Stage Renal Disease ESRD Drug Market
26. Top End Stage Renal Disease ESRD Drug Companies
27. End Stage Renal Disease ESRD Drug Market Opportunities And Strategies
28. End Stage Renal Disease ESRD Drug Market, Conclusions And Recommendations
29. Appendix
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
